Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Equity Capital Markets

VISEN Pharmaceuticals / Equity Capital Markets

<ul>
<li>Visen Pharmaceuticals is looking at raising up to USD 300m to list in Hong Kong.</li>
<li>The company has passed the hearing for the listing and filed a new version of the prospectus.</li>
<li>We look at the difference between previous filing and current filing. Most of the changes are not critical but we think overall it doesn’t look good.</li>
</ul>


Visen Pharmaceuticals is looking at raising up to USD 300m to list in Hong Kong.
The company has passed the hearing for the listing and filed a new version of the prospectus.
We look at the difference between previous filing and current filing. Most of the changes are not critical but we think overall it doesn’t look good.


Visen Pharmaceuticals (维升药业) IPO: PHIP Updates Don't Look Positive

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

<ul>
<li>All the three candidates lonapegsomatropin, TransCon CNP, palopegteriparatide in the pipeline of VISEN are based on Exclusive License Agreements with Ascendis Pharma. So, there're concerns about VISEN's independent R&amp;D capabilities.</li>
<li>VBP would destroy the price system of growth hormone market in China, and market size would shrink due to price reduction and decreasing demand as fewer babies will be born.</li>
<li>Post investment valuation reached US$1.03 billion. Since leading domestic companies have dominated the market, it’s not easy for VISEN to break through. Valuation of VISEN could be lower than peers.</li>
</ul>


All the three candidates lonapegsomatropin, TransCon CNP, palopegteriparatide in the pipeline of VISEN are based on Exclusive License Agreements with Ascendis Pharma. So, there're concerns about VISEN's independent R&amp;D capabilities.
VBP would destroy the price system of growth hormone market in China, and market size would shrink due to price reduction and decreasing demand as fewer babies will be born.
Post investment valuation reached US$1.03 billion. Since leading domestic companies have dominated the market, it’s not easy for VISEN to break through. Valuation of VISEN could be lower than peers.


Pre-IPO VISEN Pharmaceuticals (PHIP Updates) - Some Points Worth the Attention

<ul>
<li>Visen Pharmaceuticals is looking at raising up to USD 300m to list in Hong Kong.</li>
<li>We look at the company’s core product and highlight two unfavorable trends.</li>
<li>We are not excited about the company’s fundamentals, and are not keen in the deal.</li>
</ul>


Visen Pharmaceuticals is looking at raising up to USD 300m to list in Hong Kong.
We look at the company’s core product and highlight two unfavorable trends.
We are not excited about the company’s fundamentals, and are not keen in the deal.


Visen Pharmaceuticals IPO: Unfavorable Trends

Quantitative Analysis

<ul>
<li>We analyze the weekly Shanghai/Shenzhen northbound Connect flows with our data engine for record date as of Aug 5th.</li>
<li>Outflows from financials, industrials, materials were offset by inflows into information technology, consumer staples and health care.</li>
<li>We highlight outflows from Sanhua, Baoshan Iron, Sungrow, Han's Laser, Changchun High &amp; New Tech.</li>
</ul>


We analyze the weekly Shanghai/Shenzhen northbound Connect flows with our data engine for record date as of Aug 5th.
Outflows from financials, industrials, materials were offset by inflows into information technology, consumer staples and health care.
We highlight outflows from Sanhua, Baoshan Iron, Sungrow, Han's Laser, Changchun High &amp; New Tech.


Northbound Flows: Sanhua, Baoshan Iron, Sungrow, Han's Laser, Changchun High

Equity Bottom-Up

Anhui Anke Biotechnology (Group) / Equity Bottom-Up

Anhui Anke Biotechnology (Group) (300009 CH)

<ul>
<li>The recent plunge in share price of <a href="https://www.smartkarma.com/entities/anhui-anke-biotechnology-group-co-ltd" target="_blank" data-smartkarma-citation="entities:11475:1" rel="noopener">Anhui Anke Biotechnology </a> and <a href="https://www.smartkarma.com/entities/changchun-high-new-technology-industry-group-inc-a" target="_blank" data-smartkarma-citation="entities:1371:1" rel="noopener">Changchun High &amp; New Tech (000661 CH)</a> (CCHT) was mainly due to the volume-based purchase (VBP) on recombinant human growth hormone. </li>
<li>The best result is both CCHT and Anke quit this VBP.However,if CCHT quits but Anke wins the bidding and applies low-price strategy,CCHT couldn’t keep its price system and market share. </li>
<li>Overall, growth hormone is a market with increasing competition and shrinking market size as fewer babies are born in China. So, developing more new indications would be the way out.</li>
</ul>


The recent plunge in share price of Anhui Anke Biotechnology  and Changchun High &amp; New Tech (000661 CH) (CCHT) was mainly due to the volume-based purchase (VBP) on recombinant human growth hormone. 
The best result is both CCHT and Anke quit this VBP.However,if CCHT quits but Anke wins the bidding and applies low-price strategy,CCHT couldn’t keep its price system and market share. 
Overall, growth hormone is a market with increasing competition and shrinking market size as fewer babies are born in China. So, developing more new indications would be the way out.


Anke Biotechnology (300009CH) Vs Changchun High & New Tech (000661CH)-Growth Hormone VBP and Outlook

China

Changchun High & New Technology Industry (Group) Inc. is an investment holding company.  Through its subsidiaries, the Company manufactures biopharmaceuticals and Chinese traditional medicines, constructs infrastructure facilities, manufactures electrolytic condensers, and develops and manages real estate.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Changchun High & New Tech A (000661 CH)

Visen Pharmaceuticals (维升药业) IPO: PHIP Updates Don't Look Positive

Visen Pharmaceuticals plans to raise up to USD 300m for a Hong Kong listing. We look at changes to prospectus, which don't make the company look...

Ke Yan, CFA, FRM

Pre-IPO VISEN Pharmaceuticals (PHIP Updates) - Some Points Worth the Attention

Concerns arise over VISEN's R&D capabilities, facing challenges in a competitive market with potential price system disruption and limited market...

Xinyao (Criss) Wang

Visen Pharmaceuticals IPO: Unfavorable Trends

Visen Pharmaceuticals plans to raise $300m for a Hong Kong listing, but concerns about their core product and unfavorable trends make us not keen...

Ke Yan, CFA, FRM

Northbound Flows: Sanhua, Baoshan Iron, Sungrow, Han's Laser, Changchun High

Northbound Shanghai/Shenzhen connect recorded outflows of USD 114m last week. We highlight outflows from Sanhua, Baoshan Iron, Sungrow, Han's...

Ke Yan, CFA, FRM

Anke Biotechnology (300009CH) Vs Changchun High & New Tech (000661CH)-Growth Hormone VBP and Outlook

We analyzed the impact and outlook of growth hormone VBP that led to share price plunge of Anke and CCHT. We also analyzed the bidding strategy for...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Visen Pharmaceuticals (维升药业) IPO: PHIP Updates Don't Look Positive

​Visen Pharmaceuticals plans to raise up to USD 300m for a Hong Kong listing. We look at changes to prospectus, which don't make the company look...

Ke Yan, CFA, FRM

Pre-IPO VISEN Pharmaceuticals (PHIP Updates) - Some Points Worth the Attention

​Concerns arise over VISEN's R&D capabilities, facing challenges in a competitive market with potential price system disruption and limited market...

Xinyao (Criss) Wang

Visen Pharmaceuticals IPO: Unfavorable Trends

​Visen Pharmaceuticals plans to raise $300m for a Hong Kong listing, but concerns about their core product and unfavorable trends make us not keen...

Ke Yan, CFA, FRM

Northbound Flows: Sanhua, Baoshan Iron, Sungrow, Han's Laser, Changchun High

Northbound Shanghai/Shenzhen connect recorded outflows of USD 114m last week. We highlight outflows from Sanhua, Baoshan Iron, Sungrow, Han's...

Ke Yan, CFA, FRM

Anke Biotechnology (300009CH) Vs Changchun High & New Tech (000661CH)-Growth Hormone VBP and Outlook

We analyzed the impact and outlook of growth hormone VBP that led to share price plunge of Anke and CCHT. We also analyzed the bidding strategy for...

Xinyao (Criss) Wang

Visen Pharmaceuticals plans to raise up to USD 300m for a Hong Kong listing. We look at changes to prospectus, which don't make the company look...

Concerns arise over VISEN's R&D capabilities, facing challenges in a competitive market with potential price system disruption and limited market...

Visen Pharmaceuticals plans to raise $300m for a Hong Kong listing, but concerns about their core product and unfavorable trends make us not keen...